A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel
Abstract The present explorative study was initiated to evaluate the clinical value of 18F-FES PET/CT in monitoring the change of estrogen receptor (ER) expression and potential predictive value in metastatic breast cancer patients. Twenty-two pathology-confirmed breast cancer patients were prospect...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5f858afef231473483d6e91ca47f4bd9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5f858afef231473483d6e91ca47f4bd9 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5f858afef231473483d6e91ca47f4bd92021-12-02T16:07:04ZA preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel10.1038/s41598-017-06903-82045-2322https://doaj.org/article/5f858afef231473483d6e91ca47f4bd92017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06903-8https://doaj.org/toc/2045-2322Abstract The present explorative study was initiated to evaluate the clinical value of 18F-FES PET/CT in monitoring the change of estrogen receptor (ER) expression and potential predictive value in metastatic breast cancer patients. Twenty-two pathology-confirmed breast cancer patients were prospectively enrolled and randomly divided into two groups (T: docetaxel, n = 14 and TF: docetaxel + fulvestrant, n = 8). The percentage of patients without disease progression after 12 months (PFS > 12 months) was 62.5% in group TF compared with 21.4% in group T (P = 0.08). According to 18F-FES PET/CT scans, the SUVmax (maximum standard uptake value) of all the metastatic lesions decreased in group TF after 2 cycles of treatment (6 weeks ± 3 days). However, 6 of 9 patients in group T had at least one lesion with higher post-treatment SUVmax. There was a significant difference in the reduction of ER expression between these two groups (P = 0.028). In group TF, the patients with PFS > 12 months had significantly greater SUVmax changes of 18F-FES than those with PFS < 12 months (PFS > 12 months: 91.0 ± 12.0% versus PFS < 12 months: 20.7 ± 16.2%; t = −4.64, P = 0.01). Our preliminary study showed that 18F-FES PET/CT, as a noninvasive method to monitor ER expression, could be utilized to predict prognosis based on changes in SUVmax.Chengcheng GongZhongyi YangYifei SunJian ZhangChunlei ZhengLeiping WangYongping ZhangJing XueZhifeng YaoHerong PanBiyun WangYingjian ZhangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Chengcheng Gong Zhongyi Yang Yifei Sun Jian Zhang Chunlei Zheng Leiping Wang Yongping Zhang Jing Xue Zhifeng Yao Herong Pan Biyun Wang Yingjian Zhang A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel |
| description |
Abstract The present explorative study was initiated to evaluate the clinical value of 18F-FES PET/CT in monitoring the change of estrogen receptor (ER) expression and potential predictive value in metastatic breast cancer patients. Twenty-two pathology-confirmed breast cancer patients were prospectively enrolled and randomly divided into two groups (T: docetaxel, n = 14 and TF: docetaxel + fulvestrant, n = 8). The percentage of patients without disease progression after 12 months (PFS > 12 months) was 62.5% in group TF compared with 21.4% in group T (P = 0.08). According to 18F-FES PET/CT scans, the SUVmax (maximum standard uptake value) of all the metastatic lesions decreased in group TF after 2 cycles of treatment (6 weeks ± 3 days). However, 6 of 9 patients in group T had at least one lesion with higher post-treatment SUVmax. There was a significant difference in the reduction of ER expression between these two groups (P = 0.028). In group TF, the patients with PFS > 12 months had significantly greater SUVmax changes of 18F-FES than those with PFS < 12 months (PFS > 12 months: 91.0 ± 12.0% versus PFS < 12 months: 20.7 ± 16.2%; t = −4.64, P = 0.01). Our preliminary study showed that 18F-FES PET/CT, as a noninvasive method to monitor ER expression, could be utilized to predict prognosis based on changes in SUVmax. |
| format |
article |
| author |
Chengcheng Gong Zhongyi Yang Yifei Sun Jian Zhang Chunlei Zheng Leiping Wang Yongping Zhang Jing Xue Zhifeng Yao Herong Pan Biyun Wang Yingjian Zhang |
| author_facet |
Chengcheng Gong Zhongyi Yang Yifei Sun Jian Zhang Chunlei Zheng Leiping Wang Yongping Zhang Jing Xue Zhifeng Yao Herong Pan Biyun Wang Yingjian Zhang |
| author_sort |
Chengcheng Gong |
| title |
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel |
| title_short |
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel |
| title_full |
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel |
| title_fullStr |
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel |
| title_full_unstemmed |
A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel |
| title_sort |
preliminary study of 18f-fes pet/ct in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/5f858afef231473483d6e91ca47f4bd9 |
| work_keys_str_mv |
AT chengchenggong apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT zhongyiyang apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT yifeisun apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT jianzhang apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT chunleizheng apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT leipingwang apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT yongpingzhang apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT jingxue apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT zhifengyao apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT herongpan apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT biyunwang apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT yingjianzhang apreliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT chengchenggong preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT zhongyiyang preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT yifeisun preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT jianzhang preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT chunleizheng preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT leipingwang preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT yongpingzhang preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT jingxue preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT zhifengyao preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT herongpan preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT biyunwang preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel AT yingjianzhang preliminarystudyof18ffespetctinpredictingmetastaticbreastcancerinpatientsreceivingdocetaxelorfulvestrantwithdocetaxel |
| _version_ |
1718384777836363776 |